ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Trial Details

NCT ID
NCT06838676
Phase
PHASE2
Sponsor
Nationwide Children's Hospital
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • ACT001
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Miami, Florida, United States|25.77427,-80.19366
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Ann Arbor, Michigan, United States|42.27756,-83.74088

Key Eligibility Criteria

  • Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollment.
  • Diagnosis:
  • Cohort A: Newly Diagnosed DIPG
  • Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons) …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →